Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(13):907; doi:10.1093/jnci/djn226
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Imatinib-Resistant Leukemia and LYN Kinase

The tyrosine kinase inhibitor imatinib is used to treat chronic myelogenous leukemia (CML). Failure of imatinib treatment is associated with mutations in the BCR-ABL kinase in some, but not all, CML patients. The LYN kinase regulates survival and responsiveness of CML cells to inhibition of the BCR-ABL kinase, and differences in LYN regulation have been found between imatinib-sensitive and imatinib-resistant CML cell lines. Wu et al. (p. 926) investigated whether LYN kinase was involved in imatinib-resistant CML by evaluating mononuclear cells from 12 imatinib-resistant CML patients with BCR-ABL mutation–negative leukemia and . . . [Full Text of this Article]

CHD5 is a Tumor Suppressor Gene for Neuroblastoma

Immunization with GCC to Prevent Colon Cancer Metastasis

Fine Mapping of a Cancer Susceptibity Locus

NSAID Use and Melanoma Incidence in a Cohort Study

Evaluating Large Epidemiological Studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

A Large Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Melanoma Incidence
Maryam M. Asgari, Sonia S. Maruti, and Emily White
J Natl Cancer Inst 2008 100: 967-971. [Abstract] [Full Text] [PDF]

CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
Tomoyuki Fujita, Jun Igarashi, Erin R. Okawa, Takahiro Gotoh, Jayanthi Manne, Venkatadri Kolla, Jessica Kim, Huaqing Zhao, Bruce R. Pawel, Wendy B. London, John M. Maris, Peter S. White, and Garrett M. Brodeur
J Natl Cancer Inst 2008 100: 940-949. [Abstract] [Full Text] [PDF]

Guanylyl Cyclase C–Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity
Adam E. Snook, Benjamin J. Stafford, Peng Li, Gene Tan, Lan Huang, Ruth Birbe, Stephanie Schulz, Matthias J. Schnell, Mathew Thakur, Jay L. Rothstein, Laurence C. Eisenlohr, and Scott A. Waldman
J Natl Cancer Inst 2008 100: 950-961. [Abstract] [Full Text] [PDF]

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
Ji Wu, Feng Meng, Ling-Yuan Kong, Zhenghong Peng, Yunming Ying, William G. Bornmann, Bryant G. Darnay, Betty Lamothe, Hanshi Sun, Moshe Talpaz, and Nicholas J. Donato
J Natl Cancer Inst 2008 100: 926-939. [Abstract] [Full Text] [PDF]

Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert
Maya Ghoussaini, Honglin Song, Thibaud Koessler, Ali Amin Al Olama, Zsofia Kote-Jarai, Kristy E. Driver, Karen A. Pooley, Susan J. Ramus, Susanne Krüger Kjaer, Estrid Hogdall, Richard A. DiCioccio, Alice S. Whittemore, Simon A. Gayther, Graham G. Giles, Michelle Guy, Stephen M. Edwards, Jonathan Morrison, Jenny L. Donovan, Freddie C. Hamdy, David P. Dearnaley, Audrey T. Ardern-Jones, Amanda L. Hall, Lynne T. O'Brien, Beatrice N. Gehr-Swain, Rosemary A. Wilkinson, Paul M. Brown, John L. Hopper, David E. Neal, Paul D. P. Pharoah, Bruce A. J. Ponder, Rosalind A. Eeles, Douglas F. Easton, Alison M. Dunning, and for the UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology and the UK ProtecT Study Collaborators
J Natl Cancer Inst 2008 100: 962-966. [Abstract] [Full Text] [PDF]

Criteria for the Evaluation of Large Cohort Studies: An Application to the Nurses’ Health Study
Graham A. Colditz and Deborah M. Winn
J Natl Cancer Inst 2008 100: 918-925. [Abstract] [Full Text] [PDF]

Persistent LYN Signaling in Imatinib-Resistant, BCR-ABL–Independent Chronic Myelogenous Leukemia
Thomas O'Hare, Christopher A. Eide, and Michael W. Deininger
J Natl Cancer Inst 2008 100: 908-909. [Extract] [Full Text] [PDF]